Virus for treatment of tumor
AssigneesXiamen University, Yang Sheng Tang Company, Ltd.
InventorsTong Cheng, Wei Wang, Junkai Wan, Wenkun Fu, Xiangzhong Ye, Jun Zhang, Ningshao Xia
Life of this patent
Estimating the term…
Abstract
Provided are an enterovirus D68 (EV-D68) or a modified form thereof, or a nucleic acid molecule comprising a genomic sequence or cDNA sequence of the EV-D68 or a modified form thereof, or a complementary sequence of the genomic sequence or cDNA sequence, or a pharmaceutical composition comprising the EV-D68 or a modified form thereof, or the nucleic acid molecule, and use of the EV-D68 or a modified form thereof, or the nucleic acid molecule in the manufacture of a pharmaceutical composition for treating a tumor.
Claims6
A method of treating a lymphoma, the method comprising administering by intratumoral injection, to a subject in need thereof, an effective amount of a modified EV-D68, an isolated nucleic acid molecule, or a medicament comprising the modified EV-D68, or the isolated nucleic acid molecule,
- wherein the isolated nucleic acid molecule comprises a sequence selected from the group consisting of:
- (1) a genomic sequence or cDNA sequence of the modified EV-D68;
- and
- (2) a complementary sequence of the genomic sequence or cDNA sequence;
- wherein, as compared to a genome of the wild-type EV-D68, a genome of the modified EV-D68 has a substitution of the internal ribosome entry site (IRES) sequence in a 5′ untranslated region (5′UTR) with an exogenous IRES sequence from human rhinovirus 2 (HRV2);
- and the modified EV-D68 has the genomic sequence as set forth in SEQ ID NO:
- 13 or has the cDNA sequence as set forth in SEQ ID NO:
- 8;
- and wherein the subject is a human.
A modified EV-D68, a genome of which has a substitution of the internal ribosome entry site (IRES) sequence in a 5′ untranslated region (5′UTR) with an exogenous IRES sequence from human rhinovirus 2 (HRV2) as compared to a genome of a wild-type EV-D68;
- and the modified EV-D68 has the genomic sequence as set forth in SEQ ID NO:
- 13 or has the cDNA sequence as set forth in SEQ ID NO:
- 8.
Dependencies are inferred from the claim text.